Vernalis Research, a Ligand Company, Achieves Success Milestones in...
CAMBRIDGE, England Vernalis Research, a Ligand Company, announced today that it has earned multiple success milestones under its drug discovery collaboration with Daiichi Sankyo Company, Limited...
View ArticleFive Prime Therapeutics Initiates Patient Dosing in a Phase 1 Clinical Trial...
SOUTH SAN FRANCISCO, Calif. Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced it...
View ArticleCDISC Releases Therapeutic Area User Guide to Bring Clarity to Data for...
AUSTIN, Texas CDISC is pleased to announce the release of a Therapeutic Area (TA) Standard that specifies how to structure data in clinical research studies for Colorectal Cancer. The standard,...
View ArticleVineti™がTessa Therapeutics™と提携し、がん免疫療法の前進と世界的な規模拡大を目指す
サンフランシスコ (ビジネスワイヤ) — 個別化治療のためのデジタル「記録プラットフォーム」の大手企業Vineti, Inc.は本日、新たにTessa Therapeuticsと提携関係に入り、固形腫瘍に対する個別化細胞療法のアジアと世界での前進と規模拡大を目指すと発表しました。 Tessa...
View ArticleVineti™ to Partner With Tessa Therapeutics™ to Advance and Scale Cancer...
SAN FRANCISCO Vineti, Inc., the leading digital “platform of record” for personalized therapies, today announced a new partnership with Tessa Therapeutics to advance and scale personalized cell...
View ArticleVineti™与Tessa Therapeutics合作在全球推广癌症免疫疗法
旧金山 (美国商业资讯) — Vineti, Inc.是面向个体化疗法的领先的数字“记录平台”,该公司今天宣布与Tessa Therapeutics缔结新的伙伴关系,在亚洲及全球推广实体瘤个体化细胞疗法。 Tessa Therapeutics...
View ArticleJapan-India collaboration yields a novel treatment method for male urethral...
TOKYO A novel and relatively pain-less treatment method for male urethral stricture using patients own buccal mucosal cells has been reported as successful in four out of six patients. The study has...
View Article日印の協業が尿道狭窄の新規治療法を生み出す
東京 (ビジネスワイヤ) — 患者の頬粘膜細胞を使用した男性尿道狭窄の新規治療法として、痛みが比較的少ない方法が患者6人のうち4人で成功したとの報告がなされました。本研究は、日本の生体材料技術の研究者とインドの泌尿器科医のDr Suryaprakash Vaddiの共同研究の成果として、日本泌尿器科学会の公式誌であるInternational Journal of...
View ArticleEuropean Commission Approves ALUNBRIG® (brigatinib) for ALK+ Non-Small Cell...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Commission (EC) granted marketing authorization for ALUNBRIG (brigatinib) as a...
View ArticleImpediMed’s SOZO® Digital Health Platform Voted Among Top Five Finalists for...
BRISBANE, Australia & CARLSBAD, Calif. ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status...
View ArticleCelltrion and Teva Announce FDA Approval of TRUXIMA® (rituximab-abbs), a...
INCHEON, South Korea & JERUSALEM Celltrion, Inc. (KRX:068270) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has...
View Article欧盟委员会核准ALUNBRIG® (brigatinib)用于既往接受过克唑替尼治疗的ALK+非小细胞肺癌患者,促进欧洲治疗范式
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE: 4502)今天宣布,欧盟委员会(EC)核准ALUNBRIG...
View Article欧州委員会がクリゾチニブによる前治療歴のあるALK陽性非小細胞肺がん患者の治療薬としてALUNBRIG®(ブリガチニブ)を承認し、欧州における治療パラダイ...
米マサチューセッツ州ケンブリッジ & 大阪 (ビジネスワイヤ) — 武田薬品工業株式会社(TSE:...
View ArticleTakeda to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502) today announced that data from the Phase 3 randomized, TOURMALINE-MM3 study evaluating the effect of single-agent...
View ArticleTRIGR Therapeutics Expands Bispecific Immuno-Oncology Pipeline with Exclusive...
IRVINE, Calif. & SEOUL, South Korea TRIGR Therapeutics, Inc. (“TRIGR”), and ABL Bio, Inc. (“ABL”), today announced that they have entered into a collaboration and license agreement for TR009...
View ArticleSeattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2...
BOTHELL, Wash. & CAMBRIDGE, Mass. & OSAKA, Japan Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) announced that data from the ECHELON-2 phase 3...
View Articleティジアナ、肝細胞がんにおけるMilciclibの忍容性・抗腫瘍活性を評価するための第2a相試験で患者組み入れを完了
ニューヨーク & ロンドン (ビジネスワイヤ) — 炎症/腫瘍適応症向け革新的治療薬の創薬・開発に傾注するバイオテクノロジー企業のティジアナ・ライフ・サイエンシズ(Nasdaq: TLSA / AIM:...
View Article武田呈报首个评估蛋白酶体抑制剂用于维持治疗的枢纽性3期安慰剂对照试验TOURMALINE-MM3的阳性数据
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(TSE:4502)今天宣布,3期随机TOURMALINE-MM3研究数据将于2018年12月2日周日在加州圣迭戈召开的美国血液学会(ASH)第60届年会上呈报,该研究评估NINLARO™...
View ArticleTiziana评估Milciclib用于肝细胞肝癌(HCC)耐受性及抗肿瘤活性的2a期试验完成患者征集
纽约和伦敦 (美国商业资讯) — Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS)...
View ArticleUpdated Data from Phase 1/2 Open-Label Study of BCMA-Directed CAR-T Cell...
BEERSE, Belgium The Janssen Pharmaceutical Companies of Johnson & Johnson reported today updated results from Legend Biotech Inc.’s LEGEND-2 Phase 1/2 open-label study, which evaluated the...
View Article